CYTK
Price
$62.17
Change
+$1.14 (+1.87%)
Updated
Oct 15, 11:15 AM (EDT)
Capitalization
7.3B
14 days until earnings call
Intraday Buy/Sell Signals
DARE
Price
$2.06
Change
-$0.00 (-0.00%)
Updated
Oct 15, 11:13 AM (EDT)
Capitalization
27.79M
Intraday Buy/Sell Signals
Interact to see
Advertisement

CYTK vs DARE

Header iconCYTK vs DARE Comparison
Open Charts CYTK vs DAREBanner chart's image
Cytokinetics
Price$62.17
Change+$1.14 (+1.87%)
Volume$100
Capitalization7.3B
Dare Bioscience
Price$2.06
Change-$0.00 (-0.00%)
Volume$1.64K
Capitalization27.79M
CYTK vs DARE Comparison Chart in %
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYTK vs. DARE commentary
Oct 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a Hold and DARE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 17, 2025
Stock price -- (CYTK: $61.03 vs. DARE: $2.06)
Brand notoriety: CYTK and DARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 86% vs. DARE: 59%
Market capitalization -- CYTK: $7.3B vs. DARE: $27.79M
CYTK [@Biotechnology] is valued at $7.3B. DARE’s [@Biotechnology] market capitalization is $27.79M. The market cap for tickers in the [@Biotechnology] industry ranges from $105.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.02B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 1 FA rating(s) are green whileDARE’s FA Score has 0 green FA rating(s).

  • CYTK’s FA Score: 1 green, 4 red.
  • DARE’s FA Score: 0 green, 5 red.
According to our system of comparison, CYTK is a better buy in the long-term than DARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 5 TA indicator(s) are bullish while DARE’s TA Score has 4 bullish TA indicator(s).

  • CYTK’s TA Score: 5 bullish, 4 bearish.
  • DARE’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, CYTK is a better buy in the short-term than DARE.

Price Growth

CYTK (@Biotechnology) experienced а +1.43% price change this week, while DARE (@Biotechnology) price change was -8.15% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.44%. For the same industry, the average monthly price growth was +17.42%, and the average quarterly price growth was +81.94%.

Reported Earning Dates

CYTK is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+0.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($7.3B) has a higher market cap than DARE($27.8M). CYTK YTD gains are higher at: 29.741 vs. DARE (-33.910). DARE has higher annual earnings (EBITDA): -17.84M vs. CYTK (-504.83M). CYTK has more cash in the bank: 858M vs. DARE (5.04M). DARE has less debt than CYTK: DARE (3.03M) vs CYTK (858M). CYTK has higher revenues than DARE: CYTK (85.7M) vs DARE (-17.7K).
CYTKDARECYTK / DARE
Capitalization7.3B27.8M26,270%
EBITDA-504.83M-17.84M2,829%
Gain YTD29.741-33.910-88%
P/E RatioN/A0.10-
Revenue85.7M-17.7K-484,153%
Total Cash858M5.04M17,041%
Total Debt858M3.03M28,289%
FUNDAMENTALS RATINGS
CYTK vs DARE: Fundamental Ratings
CYTK
DARE
OUTLOOK RATING
1..100
1417
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
74
Overvalued
PROFIT vs RISK RATING
1..100
65100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4065
P/E GROWTH RATING
1..100
180
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DARE's Valuation (74) in the Biotechnology industry is in the same range as CYTK (100). This means that DARE’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's Profit vs Risk Rating (65) in the Biotechnology industry is somewhat better than the same rating for DARE (100). This means that CYTK’s stock grew somewhat faster than DARE’s over the last 12 months.

CYTK's SMR Rating (100) in the Biotechnology industry is in the same range as DARE (100). This means that CYTK’s stock grew similarly to DARE’s over the last 12 months.

CYTK's Price Growth Rating (40) in the Biotechnology industry is in the same range as DARE (65). This means that CYTK’s stock grew similarly to DARE’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for DARE (80). This means that CYTK’s stock grew significantly faster than DARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTKDARE
RSI
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
73%
Momentum
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
82%
MACD
ODDS (%)
Bullish Trend 3 days ago
75%
Bearish Trend 3 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
77%
Advances
ODDS (%)
Bullish Trend 11 days ago
79%
Bullish Trend 11 days ago
78%
Declines
ODDS (%)
Bearish Trend 4 days ago
78%
Bearish Trend 7 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
83%
Aroon
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PRME5.990.34
+6.02%
Prime Medicine
RAAQ10.430.28
+2.71%
Real Asset Acquisition Corp
ENLV1.110.01
+0.91%
Enlivex Therapeutics Ltd
BOX32.65-0.10
-0.31%
BOX
LNG226.22-0.78
-0.34%
Cheniere Energy

CYTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with IONS. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then IONS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTK
1D Price
Change %
CYTK100%
+2.42%
IONS - CYTK
64%
Loosely correlated
+1.10%
MLYS - CYTK
51%
Loosely correlated
-0.58%
ARWR - CYTK
46%
Loosely correlated
-0.80%
NEVPF - CYTK
45%
Loosely correlated
N/A
CRNX - CYTK
44%
Loosely correlated
-0.86%
More

DARE and

Correlation & Price change

A.I.dvisor indicates that over the last year, DARE has been closely correlated with AZTR. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if DARE jumps, then AZTR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DARE
1D Price
Change %
DARE100%
-2.74%
AZTR - DARE
73%
Closely correlated
+8.85%
CYTK - DARE
42%
Loosely correlated
+2.42%
AXON - DARE
39%
Loosely correlated
-0.75%
AMRN - DARE
34%
Loosely correlated
+0.73%
SNTI - DARE
32%
Poorly correlated
+23.81%
More